

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8068399

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
DAVID EIZNHAMER	06/28/2023
HEIDI KRENZ	06/15/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KADMON CORPORATION, LLC
<b>Street Address:</b>	55 CORPORATE DRIVE
<b>City:</b>	BRIDGEWATER
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08807
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	18105285
<b>PCT Number:</b>	US2022037207
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	mycklena.kosloski@mcneillbaur.com, docketing@mcneillbaur.com
<b>Correspondent Name:</b>	MCNEILL BAUR PLLC
<b>Address Line 1:</b>	125 CAMBRIDGE PARK DRIVE
<b>Address Line 2:</b>	SUITE 301
<b>Address Line 4:</b>	CAMBRIDGE, MASSACHUSETTS 02140
<b>ATTORNEY DOCKET NUMBER:</b>	01183-0233-00US-KAD-T1
<b>NAME OF SUBMITTER:</b>	MYCKI E. KOSLOSKI
<b>SIGNATURE:</b>	/Mycki E. Kosloski/
<b>DATE SIGNED:</b>	07/20/2023
<b>Total Attachments: 5</b>	
source=2023-06-30_01183-0233-00US-KAD-T1_Assignment duly executed#page1.tif	
source=2023-06-30_01183-0233-00US-KAD-T1_Assignment duly executed#page2.tif	
source=2023-06-30_01183-0233-00US-KAD-T1_Assignment duly executed#page3.tif	
source=2023-06-30_01183-0233-00US-KAD-T1_Assignment duly executed#page4.tif	



ASSIGNMENT

For valuable consideration, the receipt of which I/we acknowledge, and intending to be bound legally, I/we, the undersigned sole/joint Inventor(s), each individually assign to Kadmon Corporation, LLC, a corporation formed under the laws of Delaware and having a principal place of business at 55 Corporate Drive, Bridgewater, NJ 08807, USA, and its successors, transferees, and assignees (collectively the "Assignee"), all of my/our individual and joint rights, titles, and interests throughout the world in the subject matter (the "Subject Matter") disclosed or claimed in the patents and applications listed in Schedule A (the "Patents and Applications").

This Assignment, effective as of 14 July 2022 assigns (a) the Patents and Applications and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Patents, Applications, and Granted Rights") in every country or region, (b) the right to claim priority based on and the benefit of the filing date of any of the Patents, Applications, and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment.

I/We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in my/our name(s) or in the Assignee's name.

I/We represent and warrant that I/we have the right and power to make this Assignment and that I/we have not made and will not make any other assignment that conflicts with this Assignment.

I/We will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

---

Signed at New Chicago, IL USA on this 28 day of June, 2023.  
(City, State and Nation)

Signature:   
Inventor's Name: **David EIZNHAMER**

Mailing Address: c/o Sanofi, Patent Department,  
450 Water Street, Cambridge, MA 02141,  
USA

Witnessed by:

Corinne Eiznhamer  
Signature


Corinne Eiznhamer  
Printed Name

Kathleen A. Stange  
Signature


Kathleen A. STANGE  
Printed Name


---

Signed at Ridgewood NJ, USA on this 15 day of June, 2023.  
(City, State and Nation)

Signature:   
Inventor's Name: Heidi KRENZ

Mailing Address: c/o Sanofi, Patent Department,  
450 Water Street, Cambridge, MA 02141,  
USA

Witnessed by:  
  
Signature  
William F. Gibson Sr  
Printed Name

  
Signature  
TAPPAZ BÉTON  
Printed Name

---

**ASSIGNMENT OF RIGHTS ACCEPTED BY Kadmon Corporation, LLC**

Signed at Paris, France on this 29 day of June, 2023.  
(City, State and Nation)

By: \_\_\_\_\_



**Michel MICHEL-PECHEUX**  
Head of Synthetic Molecules Patents

**SCHEDULE A**

<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>	<u>Title</u>
PCT/US2022/037207	WO	14/07/2022	METHODS OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
3,178,096	CA	14/07/2022	METHOD OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
111126529	TW	14/07/2022	METHODS OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
18/105,285	US	03/02/2023	METHODS OF ADMINISTERING BELUMOSUDIL FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE